GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Myriad Genetics Inc (NAS:MYGN) » Definitions » E10

Myriad Genetics (Myriad Genetics) E10 : $-0.16 (As of Dec. 2023)


View and export this data going back to 1995. Start your Free Trial

What is Myriad Genetics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Myriad Genetics's adjusted earnings per share data for the three months ended in Dec. 2023 was $-0.360. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-0.16 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Myriad Genetics's average E10 Growth Rate was -135.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Myriad Genetics was 150.90% per year. The lowest was -32.00% per year. And the median was 15.40% per year.

As of today (2024-04-27), Myriad Genetics's current stock price is $18.18. Myriad Genetics's E10 for the quarter that ended in Dec. 2023 was $-0.16. Myriad Genetics's Shiller PE Ratio of today is .

During the past 13 years, the highest Shiller PE Ratio of Myriad Genetics was 178.31. The lowest was 9.46. And the median was 32.42.


Myriad Genetics E10 Historical Data

The historical data trend for Myriad Genetics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myriad Genetics E10 Chart

Myriad Genetics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.43 0.99 0.74 0.45 -0.16

Myriad Genetics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.45 0.34 0.13 -0.04 -0.16

Competitive Comparison of Myriad Genetics's E10

For the Diagnostics & Research subindustry, Myriad Genetics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Myriad Genetics's Shiller PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Myriad Genetics's Shiller PE Ratio falls into.



Myriad Genetics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Myriad Genetics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.36/129.4194*129.4194
=-0.360

Current CPI (Dec. 2023) = 129.4194.

Myriad Genetics Quarterly Data

per share eps CPI Adj_EPS
201403 0.480 99.695 0.623
201406 0.430 100.560 0.553
201409 0.210 100.428 0.271
201412 0.320 99.070 0.418
201503 0.290 99.621 0.377
201506 0.260 100.684 0.334
201509 0.420 100.392 0.541
201512 0.500 99.792 0.648
201603 0.470 100.470 0.605
201606 0.320 101.688 0.407
201609 -0.020 101.861 -0.025
201612 0.090 101.863 0.114
201703 0.060 102.862 0.075
201706 0.190 103.349 0.238
201709 1.120 104.136 1.392
201712 0.430 104.011 0.535
201803 0.130 105.290 0.160
201806 0.180 106.317 0.219
201809 -0.010 106.507 -0.012
201812 0.030 105.998 0.037
201903 0.090 107.251 0.109
201906 -0.060 108.070 -0.072
201909 -0.280 108.329 -0.335
201912 -0.110 108.420 -0.131
202003 -1.550 108.902 -1.842
202006 -0.740 108.767 -0.881
202009 -0.200 109.815 -0.236
202012 -0.510 109.897 -0.601
202103 -0.520 111.754 -0.602
202106 -0.060 114.631 -0.068
202109 0.300 115.734 0.335
202112 -0.100 117.630 -0.110
202203 -0.260 121.301 -0.277
202206 -0.180 125.017 -0.186
202209 -0.430 125.227 -0.444
202212 -0.520 125.222 -0.537
202303 -0.670 127.348 -0.681
202306 -1.420 128.729 -1.428
202309 -0.750 129.860 -0.747
202312 -0.360 129.419 -0.360

Add all the adjusted EPS together and divide 10 will get our e10.


Myriad Genetics  (NAS:MYGN) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

During the past 13 years, the highest Shiller P/E Ratio of Myriad Genetics was 178.31. The lowest was 9.46. And the median was 32.42.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Myriad Genetics E10 Related Terms

Thank you for viewing the detailed overview of Myriad Genetics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Myriad Genetics (Myriad Genetics) Business Description

Traded in Other Exchanges
Address
320 Wakara Way, Salt Lake City, UT, USA, 84108
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
Executives
Richard Bryan Riggsbee officer: Chief Financial Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Daniel K Spiegelman director MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Heinrich Dreismann director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Nicole Lambert officer: Chief Operating Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Margaret Ancona officer: SVP, Chief of Staff 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Pamela Wong officer: Chief Legal Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Shereen Solaiman officer: Chief People Officer 320 WAKARA WAY, SALT LAKE CITY UT 84108
Paul Bisaro director
Dale Muzzey officer: Chief Scientific Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Kevin Richard Haas officer: Chief Technology Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Natalie Munk officer: Chief Accounting Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Lee Nisley Newcomer director 264 BUSHAWAY ROAD, WAYZATA MN 55391-1901
Rashmi Kumar director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Jayne B. Hart officer: Executive VP Human Resources 320 WAKARA WAY, SALT LAKE CITY UT 84108
Jerry S Lanchbury officer: Senior V.P. - Research 320 WAKARA WAY, SALT LAKE CITY UT 84108